Top

memo - Magazine of European Medical Oncology

Published in:

01-02-2014 | short review

Anthracycline cardiotoxicity and lymphoma

Authors: David Mayr, MD, Michael A. Fridrik, MD

Published in: memo - Magazine of European Medical Oncology | Issue 1/2014

Abstract

Anthracyclines have substantially improved the prognosis of patients with aggressive lymphoma. Increased risk of cardiotoxicity is a significant concern associated with the use of anthracyclines, particularly in patients with pre-existing heart disease, elderly or very young patients, and those with established risk factors. A prolonged infusional schedule may alleviate the toxicity, but is difficult to implement in clinical practice. The administration of dexrazoxane, a cardioprotective agent, may ameliorate cardiotoxicity associated with anthracyclines. However, it has come under scrutiny because of increased risk of hematological second malignancies particularly in children. Liposomal doxorubicin is a viable alternative with less cardiotoxicity and similar efficacy than conventional doxorubicin. Patients should be screened for heart disease and known risk factors before initiating therapy. Risk factors should be adequately controlled and alternatives should be explored in patients at risk for cardiac toxicity. Survivorship care is an integral part of treatment, and patients should be monitored for late effects of treatment.

McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976 Oct;38(4):1484–93.PubMedCrossRef

Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10(1):337.PubMedCentralPubMedCrossRef

Von Hoff DD, Layard MW, Basa P, Davis HLJ, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicininduced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710–7.PubMedCrossRef

Moser EC. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006 Apr 1;107(7):2912–9.PubMedCrossRef

Hequet O. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004 May 15;22(10):1864–71.PubMedCrossRef

Moser EC, Noordijk EM, Carde P, Tirelli U, Baars JW, Thomas J, et al. Late non-neoplastic events in patients with aggressive non-Hodgkin’s lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma. 2005 Sep;6(2):122–30.PubMedCrossRef

Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998 Aug; 25(4 Suppl. 10):72–85.PubMed

Ng AK, LaCasce A, Travis LB. Long-term complications of lymphoma and its treatment. J Clin Oncol. 2011 May 10;29(14):1885–92.PubMedCrossRef

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235–42.PubMedCrossRef

10.

Limat S. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003 Feb 1;14(2):277–81.PubMedCrossRef

11.

Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379–91.PubMedCrossRef

12.

Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, van ’t Veer MB, Baaijens MH, de Boer JP, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007 Mar 1;109(5):1878–86.PubMedCrossRef

13.

van Dalen EC, van der Pal HJ, Caron HN, Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2009;(4):CD005008.

14.

van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2005;(1):CD003917.

15.

Osby E. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003 May 15;101(10):3840–8.PubMedCrossRef

16.

Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012 Jul;13(7):696–706.PubMedCrossRef

17.

van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2008;(2):CD003917.

18.

Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007 Feb;25(5):493–500.PubMedCrossRef

19.

Walker DM, Fisher BT, Seif AE, Huang YS, Torp K, Li Y, et al. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database. Pediatr Blood Cancer. 2013 Apr;60(4):616–20.PubMedCrossRefPubMedCentral

20.

Minotti G. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004 Jun 1;56(2):185–229.PubMedCrossRef

21.

Mross K, Niemann B, Massing U, Drevs J, Unger C, Bhamra R, et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol. 2004 Dec;54(6):514–24.PubMedCrossRef

22.

Kanter PM, Bullard GA, Ginsberg RA, Pilkiewicz FG, Mayer LD, Cullis PR, et al. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo. 1993 Jan;7(1):17–26.PubMed

23.

Kanter PM, Bullard GA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo. 1993 Jan;7(1):85–95.PubMed

24.

Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002 Jan 1;94(1):25–36.PubMedCrossRef

25.

Tulpule A, Espina BM, Berman N, Buchanan LH, Smith DL, Sherrod A, et al. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin’s lymphoma. Clin Lymphoma Myeloma. 2006 Jul;7(1):59–64.PubMedCrossRef

26.

Levine AM, Tulpule A, Espina B, Sherrod A, Boswell WD, Lieberman RD, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin’s lymphoma: results of therapy and correlates of response. J Clin Oncol. 2004 Jul;22(13):2662–70.PubMedCrossRef

27.

Visani G, Ferrara F, Alesiani F, Ronconi S, Catarini M, D’adamo F, et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lymphoma. 2008 Jun;49(6):1081–6.PubMedCrossRef

28.

Luminari S, Montanini A, Caballero D, Bologna S, Notter M, Dyer MJ, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol. 2010 Jul;21(7):1492–9.PubMedCrossRef

29.

Rigacci L, Mappa S, Nassi L, Alterini R, Carrai V, Bernardi F, et al. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol. 2007 Dec;25(4):198–203.PubMedCrossRef

30.

Corazzelli G, Frigeri F, Arcamone M, Lucania A, RosariaVilla M, Morelli E, et al. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high “life threat” impact cardiopathy. Br J Haematol. 2011 Sept;154(5):579–89.PubMedCentralPubMedCrossRef

31.

Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol. 2004 Dec;31(6 Suppl. 13):53–90.PubMedCrossRef

32.

Fridrik M, Petzer A, Keil F, Willenbacher W, Jäger U, Lang A, et al. Non-pegylated liposomal doxorubicin reduces cardiotoxicity in 1st line treatment of diffuse large B-cell lymphoma (DLBCL). Final results of a randomized trial. ASH Annu Meet Abstr. 2011;118(21):2676–6.

Title: Anthracycline cardiotoxicity and lymphoma
Authors: David Mayr, MD
Michael A. Fridrik, MD
Publication date: 01-02-2014
Publisher: Springer Vienna
Published in: memo - Magazine of European Medical Oncology / Issue 1/2014
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-013-0128-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Breast cancer surveillance: nothing has changed in the past decades (?)

The importance of HPV vaccination today

Multi-gene signatures in breast cancer: actual clinical impact

Development of treatment and clinical results in childhood AML in Austria (1993–2013)

Surgical controversies in esophageal cancer

Development of treatment and clinical results in childhood acute myeloid leukemia in Slovenia in the period from 1991 to 2010

Keynote webinar | Spotlight on antibody–drug conjugates in cancer